Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00797563 · ClinicalTrials.gov registry record · NA

Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood

A NA study of Diabetes Mellitus, sponsored by Ascensia Diabetes Care.

Completed
Registry status
NA
Development phase
102
Enrollment target
1
Study location

NCT00797563: Completed NA study of Diabetes Mellitus, sponsored by Ascensia Diabetes Care.

NCT00797563 is a NA study of Diabetes Mellitus that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 102 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00797563, a NA study of Diabetes Mellitus, has completed, sponsored by Ascensia Diabetes Care.

COMPLETED
Registry status
NA
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study was to evaluate the performance of the meter system in the hands of subjects and healthcare professionals (HCPs). It also evaluated the product user guides in the hands of untrained subjects.

Primary Outcome

Subjects with diabetes and healthcare professionals (HCPs) used a new blood glucose monitoring system (BGMS) with subject capillary blood. HCPs used the new bgms with subject venous blood. All results were compared to a lab glucose method. The BGMS has programmed algorithms to provide results equivalent to either serum/plasma or whole blood glucose methods. Number of results were obtained by combining results from three lots of Contour Blood Glucose strips.

Conditions Studied

Interventions

  • DEVICE Apollo Blood Glucose Monitoring System

Study Locations (1)

New Jersey

  • Consumer Product Testing Co., Inc. - Fairfield

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2008-11
Est. Completion 2008-11
Phase NA
Ascensia Diabetes Care

42 total trials

What the finished NCT00797563 record still lists

NCT00797563 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Apollo Blood Glucose Monitoring System is the first listed.

NCT00797563 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00797563 about?

NCT00797563 is a clinical study titled "Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood". The purpose of the study was to evaluate the performance of the meter system in the hands of subjects and healthcare professionals (HCPs). It also evaluated the product user guides in the hands of untrained subjects.

What is the current status of trial NCT00797563?

This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2008-11. Estimated completion is 2008-11.

What conditions does trial NCT00797563 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT00797563?

The interventions under investigation include: Apollo Blood Glucose Monitoring System (DEVICE).

Who is sponsoring clinical trial NCT00797563?

This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00797563 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00797563's enrollment target sits among peer trials

102 117th of 208 higher than 92 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00797563, the US trial registry maintained by the National Library of Medicine. NCT00797563 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.